CTOs on the Move


 
Inogen`s mission to improve the quality of life of supplemental oxygen users began in 2001 when Mae, a beloved Grandmother, was prescribed oxygen therapy. Learn more about Mae`s Story here: http://www.inogen.com/about-inogen/meet-mae/. Inogen was founded based on our conviction that oxygen therapy technology was not keeping pace with the desired lifestyles of patients who depended on it to live longer, more fulfilling lives. We estimate that more than 2.5 million patients in the United States and more than 4.5 million patients worldwide use oxygen therapy. Our compact, lightweight and travel-approved portable oxygen concentrators are designed to free patients from heavy tanks, ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.inogen.com
  • 326 Bollay Drive
    Goleta, CA USA 93117
  • Phone: 855.631.2438

Executives

Name Title Contact Details

Similar Companies

CIMIT -Center for integration of medicine and innovative technology

CIMIT -Center for integration of medicine and innovative technology is a Boston, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

FORA

FORA is a Newbury Park, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Intellijoint Surgical

Intellijoint Surgical develops and commercializes surgical navigation solutions for total joint replacements. We are committed to improving patients` lives by providing every surgeon with effective, easy-to-use technology.

OXiGENE

OXiGENE is a biopharmaceutical company developing new and improved therapeutics that have the potential to deliver significant medical benefits to patients with cancer and serious medical conditions. Our primary focus is developing first-in-class anti-vascular drugs referred to as vascular disrupting agents (VDAs). Our lead compound in clinical development is fosbretabulin. VDAs are a new and highly differentiated class of anti-vascular drug that target existing tumor vasculature, leading to extensive tumor cell death. VDAs target the tumor vasculature rather than the tumor cells and therefore have broad potential therapeutic utility in cancer. Because VDAs act differently than anti-angiogenic drugs or cytotoxic chemotherapy drugs, VDAs are potentially complementary with anti-angiogenic drugs and chemotherapeutic agents. OXiGENE has ongoing VDA drug development programs and is committed to advancing the science of VDAs and their potential as innovative therapies to address unmet medical needs.

Dukal

Dukal Corp. is a Portland, ME-based company in the Healthcare, Pharmaceuticals, and Biotech sector.